HLB Life Science KRX:067630KOSDAQ
HLB생명과학 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days3
DART filings, 7 days0
Articles tracked4since Sep 11
In Q2 2026, HLB Life Science reported revenue of ₩14.7bn, up 24.5% year on year, and an operating loss of ₩7.6bn. HLB Life Science (HLB생명과학) appeared in 3 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 28 with 2 articles. It was most often mentioned alongside HLB Pharmaceutical and HLB.
Filing signals 4 quarters of losses Screener
HLB Life Science quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩14.7bn | +24.5% | −₩7.6bn margin −51.6% | −₩8.7bn |
| Q1 2026 | ₩15.2bn | -44.7% | −₩6.5bn margin −42.5% | −₩7.8bn |
| Q4 2025 derived | ₩10.9bn | -61.8% | −₩5.8bn margin −53.0% | ₩20.1bn |
| Q3 2025 | ₩13.6bn | -47.9% | −₩3.8bn margin −28.2% | −₩36.8bn |
| Q2 2025 | ₩11.8bn | +57.4% | −₩6.7bn margin −56.5% | −₩26.1bn |
| Q1 2025 | ₩27.5bn | +15.0% | −₩5.9bn margin −21.6% | −₩57.2bn |
| Q4 2024 derived | ₩28.7bn | +21.8% | −₩6.8bn margin −23.9% | −₩58.6bn |
| Q3 2024 | ₩26.1bn | +19.4% | −₩6.1bn margin −23.3% | ₩64.1bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
HLB Life Science top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4